Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052881 | 0.70 | HPGD (0.36) | KDM4EGAA | |
| SCHEMBL6052934 | 0.70 | HPGD (0.38) | ALDH1A1KDM4EGAA | |
| SCHEMBL15516376 | 0.68 | PIM1 (0.41) | ALDH1A1KDM4EGAA | |
| SCHEMBL6052901 | 0.68 | TSHR (0.41) | ALDH1A1KDM4EGAA | |
| SCHEMBL9322559 | 0.67 | ACHE (0.42) | ALDH1A1 | |
| SCHEMBL20600550 | 0.65 | CCR1 (0.31) | — | |
| SCHEMBL5779191 | 0.62 | CYP1A2 (0.39) | ALDH1A1 | |
| SCHEMBL7382574 | 0.61 | ALDH1A1 (0.60) | ALDH1A1KDM4EGAA | |
| SCHEMBL16986871 | 0.60 | ALDH1A1 (0.38) | ALDH1A1KDM4E | |
| SCHEMBL24814 | 0.59 | ALDH1A1 (0.62) | ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-6657065-B2 | Which are useful as microsomal triglyceride transfer protein (MTP) inhibitors | PFIZER INC | 2003-12-02 | — | — | US | disclosed |
| US-20020161233-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-10-31 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6417367-B1 | THAT ARE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS USEFUL FOR TREATING HYPERCHOLESTEROLEMIA FOR EXAMPLE; FEWER SYNTHESIS STEPS, STARTING MATERIALS ARE AN ACYL HALIDE AND M-NITROANILINE | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161233-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | ALDH1A1 721/4885ERN1 1584/4885KDM4E 1671/4885 |
| US-20020042516-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | ALDH1A1 721/4885ERN1 1584/4885KDM4E 1671/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | ALDH1A1 752/4885ERN1 3804/4885KDM4E 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.